drugset / Trial / NCT01035658
Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
In this study, patients with relapsed or refractory ovarian cancer will receive treatment with pazopanib and liposomal doxorubicin (Doxil) until disease progression or unacceptable toxicity occurs. The Phase I portion will define the dose limiting toxicity (DLT) of pazopanib and liposomal doxorubicin when administered in combination. Once the maximum tolerated dose has been identified in the Phase I portion, the Phase II portion will evaluate efficacy and safety of this combination in the same patient population.
Timeline
- Start
- 2010-01
- Primary completion
- 2012-06
- Completion
- 2014-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Doxorubicin | Other / unclassified | 30 mg | Intravenous |
| Subject | Doxorubicin | Other / unclassified | 40 mg | Intravenous |
| Subject | Pazopanib | Small molecule | 400 mg | Oral |